Cellares, an Integrated Development and Manufacturing Organization (IDMO), has successfully concluded its Technology Adoption Program (TAP) on its automated cell therapy manufacturing Cell Shuttle™ for resecabtagene autoleucel (rese-cel), also known as CABA-201. The TAP assessed the feasibility of using the Cell Shuttle platform to automate the manufacturing of Cabaletta’s rese-cel drug product, a CD19-targeting CAR T cell therapy for autoimmune diseases.
The partnership between Cellares and Cabaletta Bio aims to facilitate global expansion of rese-cel through the use of Cellares’ network of IDMO Smart Factories. This collaboration has the potential to automate, lower costs, and scale out manufacturing, ultimately meeting the total patient demand for autoimmune diseases such as myositis, scleroderma, and lupus nephritis.
Both companies are working towards manufacturing cGMP cell therapy batches to be delivered to patients. Gwendolyn Binder, president of science and technology at Cabaletta Bio, expressed excitement about the partnership and the potential to use the Cell Shuttle in clinical trials to deliver potentially curative autologous therapies to more patients.
Fabian Gerlinghaus, CEO of Cellares, highlighted the success of the TAP in demonstrating the Cell Shuttle’s effectiveness as a scalable, automated, and cost-effective platform for manufacturing cell therapies. He also emphasized that small biotech companies like Cabaletta Bio can benefit from partnering with Cellares for next-generation automation. The collaboration between Cellares and Cabaletta Bio marks a significant step towards advancing the manufacturing and delivery of cell therapies for patients with autoimmune diseases.
Source
Note: The image is for illustrative purposes only and is not the original image of the presented article.
